(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 7.79% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Pulmonx's revenue in 2026 is $88,545,000.On average, 7 Wall Street analysts forecast LUNG's revenue for 2026 to be $3,913,234,621, with the lowest LUNG revenue forecast at $3,725,321,305, and the highest LUNG revenue forecast at $4,049,069,466. On average, 7 Wall Street analysts forecast LUNG's revenue for 2027 to be $4,221,692,914, with the lowest LUNG revenue forecast at $3,911,587,370, and the highest LUNG revenue forecast at $4,464,049,985.
In 2028, LUNG is forecast to generate $4,720,007,435 in revenue, with the lowest revenue forecast at $4,193,056,091 and the highest revenue forecast at $5,078,178,917.